News

In January 2005, Ambit and Bristol-Myers Squibb entered into a drug screening collaboration in which Bristol-Myers Squibb used Ambit’s KinomeScan platform to characterize the specificity of certain Bristol-Myers

The data demonstrates that the time to disease progression with Revlimid plus dexamethasone was 49 weeks, compared with 20 weeks for placebo plus dexamethasone. The best response rate

The data presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia, showed that the drug, enzastaurin, slowed the progression of diffuse large

Although PTI-901 demonstrated meaningful relief of symptoms in the second month of treatment, the drug did not demonstrate a meaningful benefit in the third month of treatment, which

Tykerb is an orally bio-available small molecule which potently inhibits, two receptors, ErbB2 and ErbB1, and is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

Teva’s license in the US will become effective in October 2011 unless there is a pediatric extension for the drug, which would delay the entry date by six

34 adult patients with documented CD20-positive B-cell non-Hodgkin’s lymphoma were enrolled and were infused once weekly for four weeks consecutively with 120, 200, 375, or 750 mg/m2 of

Atrial fibrillation can cause the affected part of the heart to stop pumping blood properly and can bring on serious conditions such as angina and stroke. The dose-ranging

“If approved by the FDA, we believe Sebazole will provide significant patient benefits in the non-steroidal management of seborrheic dermatitis, with less risk for irritation and a more